Guizhounli Pharmaceutical Co (SHSE:603439) LT-Debt-to-Total-Asset: 0.05 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603439 Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
86 GF Score
Price ¥10.28
GF Value ¥15.20
Valuation Significantly Undervalued
! 10 Warning Signs
View Full Analysis

What is Guizhounli Pharmaceutical Co LT-Debt-to-Total-Asset?

Guizhounli Pharmaceutical Co SHSE:603439 +3.63% 86 LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus rates SHSE:603439 with a GF Score™ of 86/100 and a GF Value™ of ¥15.20 (Significantly Undervalued). The stock has 10 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Guizhounli Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.05.

Guizhounli Pharmaceutical Co's long-term debt to total assets ratio declined from Mar. 2025 (0.07) to Mar. 2026 (0.05). It may suggest that Guizhounli Pharmaceutical Co is progressively becoming less dependent on debt to grow their business.

Guizhounli Pharmaceutical Co  (SHSE:603439) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Guizhounli Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Guizhounli Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Guizhounli Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guizhounli Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Guizhounli Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.09 0.07 0.05

Guizhounli Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.06 0.06 0.05 0.05
SHSE:603439
86GF Score
Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guizhounli Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Guizhounli Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=149.747/2847.923
=0.05

Guizhounli Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=149.5/2810.723
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.05 mean?
Guizhounli Pharmaceutical Co (SHSE:603439) has a LT-Debt-to-Total-Asset of 0.05 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Guizhounli Pharmaceutical Co and its competitors.
Is Guizhounli Pharmaceutical Co's LT-Debt-to-Total-Asset too high?
Guizhounli Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.05. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's LT-Debt-to-Total-Asset compare to ZTS?
Guizhounli Pharmaceutical Co's LT-Debt-to-Total-Asset of 0.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Guizhounli Pharmaceutical Co and its competitors. Guizhounli Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥15.20, compared to a current price of ¥10.28 — trading 32.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.05. Guizhounli Pharmaceutical Co's overall GF Score™ is 86/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?

Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥10.28 is trading 32.4% below its estimated GF Value™ of ¥15.20. GuruFocus considers Guizhounli Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for SHSE:603439:

  • LT-Debt-to-Total-Asset: 0.05
  • GF Value™: ¥15.20 vs. price of ¥10.28 (32.4% below fair value)
  • GF Score™: 86/100 with 10 warning signs

No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guizhounli Pharmaceutical Co Business Description

Address Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
86GF Score

Get the complete analysis for SHSE:603439

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥10.28
Price
¥15.20
GF Value